Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 29.26
(0.97%)
CNY 29.26
(0.97%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.19 Billion CNY | -36.3% |
| 2022 | 5.01 Billion CNY | 18.63% |
| 2021 | 4.22 Billion CNY | 53.05% |
| 2020 | 2.76 Billion CNY | 33.48% |
| 2019 | 2.06 Billion CNY | 3.4% |
| 2018 | 2 Billion CNY | 26.93% |
| 2017 | 1.57 Billion CNY | 2.81% |
| 2016 | 1.53 Billion CNY | 47.13% |
| 2015 | 1.04 Billion CNY | 4.2% |
| 2014 | 1 Billion CNY | 66.14% |
| 2013 | 602.22 Million CNY | 41.61% |
| 2012 | 425.26 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.96 Billion CNY | -8.99% |
| 2024 Q1 | 3.22 Billion CNY | 0.82% |
| 2024 Q2 | 3.25 Billion CNY | 1.13% |
| 2023 Q4 | 3.19 Billion CNY | -8.35% |
| 2023 FY | 3.19 Billion CNY | -36.3% |
| 2023 Q1 | 4.38 Billion CNY | -12.51% |
| 2023 Q2 | 3.85 Billion CNY | -12.12% |
| 2023 Q3 | 3.48 Billion CNY | -9.6% |
| 2022 Q3 | 5.34 Billion CNY | -1.21% |
| 2022 Q2 | 5.41 Billion CNY | 5.86% |
| 2022 Q1 | 5.11 Billion CNY | 20.96% |
| 2022 FY | 5.01 Billion CNY | 18.63% |
| 2022 Q4 | 5.01 Billion CNY | -6.22% |
| 2021 Q1 | 3.32 Billion CNY | 20.25% |
| 2021 Q3 | 3.86 Billion CNY | 6.94% |
| 2021 Q4 | 4.22 Billion CNY | 9.49% |
| 2021 FY | 4.22 Billion CNY | 53.05% |
| 2021 Q2 | 3.61 Billion CNY | 8.7% |
| 2020 Q4 | 2.76 Billion CNY | -6.03% |
| 2020 FY | 2.76 Billion CNY | 33.48% |
| 2020 Q1 | 2.15 Billion CNY | 4.13% |
| 2020 Q2 | 2.73 Billion CNY | 26.76% |
| 2020 Q3 | 2.93 Billion CNY | 7.61% |
| 2019 FY | 2.06 Billion CNY | 3.4% |
| 2019 Q4 | 2.06 Billion CNY | -3.85% |
| 2019 Q3 | 2.15 Billion CNY | -0.18% |
| 2019 Q2 | 2.15 Billion CNY | 2.43% |
| 2019 Q1 | 2.1 Billion CNY | 5.17% |
| 2018 Q1 | 1.59 Billion CNY | 0.86% |
| 2018 Q2 | 1.89 Billion CNY | 19.32% |
| 2018 FY | 2 Billion CNY | 26.93% |
| 2018 Q3 | 2.05 Billion CNY | 8.23% |
| 2018 Q4 | 2 Billion CNY | -2.54% |
| 2017 Q3 | 1.73 Billion CNY | 6.75% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 1.57 Billion CNY | 2.81% |
| 2017 Q2 | 1.62 Billion CNY | 0.0% |
| 2017 Q4 | 1.57 Billion CNY | -9.26% |
| 2016 Q4 | 1.53 Billion CNY | 0.0% |
| 2016 FY | 1.53 Billion CNY | 47.13% |
| 2015 Q3 | 1.01 Billion CNY | 0.0% |
| 2015 FY | 1.04 Billion CNY | 4.2% |
| 2015 Q4 | 1.04 Billion CNY | 2.6% |
| 2014 FY | 1 Billion CNY | 66.14% |
| 2013 FY | 602.22 Million CNY | 41.61% |
| 2012 FY | 425.26 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 8.84 Billion CNY | 63.874% |
| Joinn Laboratories(China)Co.,Ltd. | 1.67 Billion CNY | -91.149% |
| WuXi AppTec Co., Ltd. | 17.66 Billion CNY | 81.915% |
| Autobio Diagnostics Co., Ltd. | 2.85 Billion CNY | -11.851% |
| Thalys Medical Technology Group Inc. | 2.02 Billion CNY | -57.63% |
| Chemclin Diagnostics Co., Ltd. | 431.76 Million CNY | -640.064% |